FDA approves Roche's Lucentis (ranibizumab injection) for treatment of diabetic retinopathy in people with diabetic macular edema

Roche announced today that the U.S. Food and Drug Administration (FDA) approved Lucentis (ranibizumab injection) for the treatment of diabetic retinopathy (DR), in people with diabetic macular edema (DME). DME impacts nearly 750,000 Americans, about 10 percent of people with DR.
Source: Roche Media News - Category: Pharmaceuticals Source Type: news